Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44
HOS-112157 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ
with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a
narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot
alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of
REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose
combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) cisapride (HOS-085610) pibrentasvir (HOS-086298) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) glecaprevir (HOS-086297) grazoprevir (HOS-108815) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) terfenadine (HOS-085607) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt
Gegenanzeigen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-112508 · Präparat HOS-093697
Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage c4b3ab94616e0322b411e03f5d763dea373d5e89153f1fbbe4a0dce4d84df7d4 · Zeichen 93–181 im Abschnitt
Gegenanzeigen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 21
HOS-112570 · Präparat HOS-093697
Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage c4b3ab94616e0322b411e03f5d763dea373d5e89153f1fbbe4a0dce4d84df7d4 · Zeichen 93–181 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-112511 · Präparat HOS-093697
Effect aprepitant on the pharmacokinetics of other active substances
CYP3A4 inhibition
As a moderate inhibitor of CYP3A4, aprepitant (125 mg/80 mg) can increase plasma concentrations of
co-administered active substances that are metabolised through CYP3A4. The total exposure of orally
administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment
with EMEND; the effect of aprepitant on the plasma concentrations of intravenously administered
CYP3A4 substrates is expected to be smaller. EMEND must not be used concurrently with pimozide,
terfenadine, astemizole, or cisapride (see section 4.3). Inhibition of CYP3A4 by aprepitant could result
in elevated plasma concentrations of these active substances, potentially causing serious or
life-threatening reactions. Caution is advised during concomitant administration of EMEND and orally
administered active substances that are metabolised primarily through CYP3A4 and with a narrow
therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine,
ergotamine, fentanyl, and quinidine (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 95169de188fddd2d62217733cbc8b18b68fe7db2d6460ff4dc5aa2b0e655690d · Zeichen 490–1616 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-112572 · Präparat HOS-093697
Effect of aprepitant on the pharmacokinetics of other active substances
CYP3A4 inhibition
As a moderate inhibitor of CYP3A4, aprepitant (125 mg/80 mg) can increase plasma concentrations of
co-administered active substances that are metabolised through CYP3A4. The total exposure of orally
administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment
with EMEND; the effect of aprepitant on the plasma concentrations of intravenously administered
CYP3A4 substrates is expected to be smaller. EMEND must not be used concurrently with pimozide,
terfenadine, astemizole, or cisapride (see section 4.3). Inhibition of CYP3A4 by aprepitant could result
in elevated plasma concentrations of these active substances, potentially causing serious or
life-threatening reactions. Caution is advised during concomitant administration of EMEND and orally
administered active substances that are metabolised primarily through CYP3A4 and with a narrow
therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine,
ergotamine, fentanyl, and quinidine (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage b50d17ed63c48d4d594d584aa63f6b0c29730ab2069a1d8a4a7e4e6f403046fb · Zeichen 431–1560 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-114225 · Präparat HOS-094063
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide,
halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal
products, leading to QTc prolongation and rare occurrences of torsade de pointes (see sections 4.4 and
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 817191be2c62553dd1f5acd6d8da62bbd0d99e32f150868ed7a088281a031409 · Zeichen 152–453 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.3 · PDF-Seite 22
HOS-114277 · Präparat HOS-094063
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide,
halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal
products, leading to QTc prolongation and rare occurrences of torsade de pointes (see sections 4.4 and
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 817191be2c62553dd1f5acd6d8da62bbd0d99e32f150868ed7a088281a031409 · Zeichen 152–453 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 44
HOS-114330 · Präparat HOS-094063
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide,
halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal
products, leading to QTc prolongation and rare occurrences of torsade de pointes (see sections 4.4 and
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 817191be2c62553dd1f5acd6d8da62bbd0d99e32f150868ed7a088281a031409 · Zeichen 152–453 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.3 · PDF-Seite 68
HOS-114384 · Präparat HOS-094063
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide,
halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal
products, leading to QTc prolongation and rare occurrences of torsade de pointes (see sections 4.4 and
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 817191be2c62553dd1f5acd6d8da62bbd0d99e32f150868ed7a088281a031409 · Zeichen 152–453 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 7
HOS-114239 · Präparat HOS-094063
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates)
Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or
quinidine is contraindicated. Co-administration may result in increased plasma concentrations of these
medicinal products, leading to QTc prolongation and rare occurrences of torsade de pointes (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 95bb666ba4cffd6e8f030772e59fe9a9baba17f622cca7be3a64dda0f32bd49f · Zeichen 4571–4976 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-114289 · Präparat HOS-094063
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates)
Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or
quinidine is contraindicated. Co-administration may result in increased plasma concentrations of these
medicinal products, leading to QTc prolongation and rare occurrences of torsade de pointes (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 95bb666ba4cffd6e8f030772e59fe9a9baba17f622cca7be3a64dda0f32bd49f · Zeichen 4045–4450 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 47
HOS-114342 · Präparat HOS-094063
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates)
Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or
quinidine is contraindicated. Co-administration may result in increased plasma concentrations of these
medicinal products, leading to QTc prolongation and rare occurrences of torsade de pointes (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 95bb666ba4cffd6e8f030772e59fe9a9baba17f622cca7be3a64dda0f32bd49f · Zeichen 3480–3885 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 71
HOS-114395 · Präparat HOS-094063
Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates)
Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or
quinidine is contraindicated. Co-administration may result in increased plasma concentrations of these
medicinal products, leading to QTc prolongation and rare occurrences of torsade de pointes (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) halofantrine (HOS-085606) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 95bb666ba4cffd6e8f030772e59fe9a9baba17f622cca7be3a64dda0f32bd49f · Zeichen 4046–4451 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) propafenone (HOS-084530) cisapride (HOS-085610) lovastatin (HOS-086157) flecainide (HOS-086203) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) metoprolol (HOS-090094) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 20
HOS-114845 · Präparat HOS-094169
Inhibition of CYP 2D6
by tipranavir/r
Antihistamines
Astemizole Based on theoretical The concomitant use of Aptivus,
Terfenadine considerations, tipranavir, co- co-administered with low dose
No interaction study administered with low dose ritonavir, with astemizole or
performed ritonavir, is expected to increase terfenadine is contraindicated due
astemizole and terfenadine to potential serious and/or life
concentrations. threatening events (see
section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Ergot derivatives
Dihydroergotamine Based on theoretical The concomitant use of Aptivus,
Ergonovine considerations, tipranavir, co- co-administered with low dose
Ergotamine administered with low dose ritonavir, with
Methylergonovine ritonavir, is expected to increase dihydroergotamine, ergonovine,
No interaction study dihydroergotamine, ergonovine, ergotamine or methylergonovine
performed ergotamine and is contraindicated due to potential
methylergonovine concentrations. serious and/or life threatening
events (see section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Gastrointestinal motility agents
Cisapride Based on theoretical The concomitant use of Aptivus,
No interaction study considerations, tipranavir, co- co-administered with low dose
performed administered with low dose ritonavir, with cisapride is
ritonavir, is expected to increase contraindicated due to potential
cisapride concentrations. serious and/or life threatening
events (see section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylergonovine (HOS-086155) cisapride (HOS-085610) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) terfenadine (HOS-085607) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 0bc47b611eec8274771aaf2f47f7c4c8b088648012f479c3407b7ce6fe3032f6 · Zeichen 50501–52945 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-115308 · Präparat HOS-094267
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. HIV protease inhibitors,
antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins, oral
contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section for
antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is recommended. A
dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage d0f42d8f593222b754dd51125c16cac4738a18df13892197979077dd910686ea · Zeichen 1429–1956 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg hard capsules · Abschnitt 4.5 · PDF-Seite 16
HOS-115381 · Präparat HOS-094267
At therapeutic concentrations, stiripentol significantly inhibits several CYP450 isoenzymes: for
example, CYP2C19, CYP2D6 and CYP3A4. As a result, pharmacokinetic interactions of metabolic
origin with other medicines may be expected. These interactions may result in increased systemic
levels of these active substances that may lead to enhanced pharmacological effects and to an increase
in adverse reactions.
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. HIV protease inhibitors,
antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins, oral
contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section for
antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is recommended. A
dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) lead (HOS-085592) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage 461e95e0afe38eed84d94f312102213f5ddd1a0784f12f64d24f311bc3bbb136 · Zeichen 1019–1957 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 250 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 27
HOS-115415 · Präparat HOS-094267
At therapeutic concentrations, stiripentol significantly inhibits several CYP450 isoenzymes: for
example, CYP2C19, CYP2D6 and CYP3A4. As a result, pharmacokinetic interactions of metabolic
origin with other medicines may be expected. These interactions may result in increased systemic
levels of these active substances that may lead to enhanced pharmacological effects and to an increase
in adverse reactions.
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. several HIV protease
inhibitors, antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins,
oral contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section
for antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is
recommended. A dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) lead (HOS-085592) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage 890a2b068107a3872634a445054ed75c39b3905a5e8af1130059232a7739a5f2 · Zeichen 1018–1964 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 38
HOS-115450 · Präparat HOS-094267
Caution must be exercised if clinical circumstances require combining stiripentol with substances
metabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. several HIV protease
inhibitors, antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins,
oral contraceptives, codeine) due to the increased risk of adverse reactions (see further in this section
for antiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is
recommended. A dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) codeine (HOS-090544) protease (HOS-085623) chlorpheniramine (HOS-115313) calcium (HOS-085615) astemizole (HOS-085608) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage b84435ca1a4cdf73091bf84be97bf4ecc4ba97440a16fe3b236aaf5fc17b9d87 · Zeichen 1430–1965 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) cobicistat (HOS-088111) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.